Clinicians clash with consumer groups over possible Depo ban.
D000569:Americas; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D019049:Developed Countries; D004467:Economics; D005193:Family Planning Services; D006077:Government Agencies; D006262:Health; D007267:Injections; D017258:Medroxyprogesterone Acetate; D009656:North America; D009938:Organizations; D011057:Politics; D011634:Public Health; D011639:Public Opinion; D012449:Safety; D014481:United States; D014486:United States Food and Drug Administration; D014492:United States Public Health Service; D014930:Women
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate
Americas; Consumption; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Depo-provera; Developed Countries; Economic Factors; Family Planning; Government Agencies; Health; Injectables; Interest Groups; Macroeconomic Factors; Medroxyprogesterone Acetate; North America; Northern America; Organizations; Political Factors; Public Health; Safety; United States; Usfda; Usphs; Women's Groups